[go: up one dir, main page]

WO2000067738A3 - The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders - Google Patents

The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders Download PDF

Info

Publication number
WO2000067738A3
WO2000067738A3 PCT/US2000/012339 US0012339W WO0067738A3 WO 2000067738 A3 WO2000067738 A3 WO 2000067738A3 US 0012339 W US0012339 W US 0012339W WO 0067738 A3 WO0067738 A3 WO 0067738A3
Authority
WO
WIPO (PCT)
Prior art keywords
tyrosine kinase
protein tyrosine
prophylactic
kinase pathway
therapeutic treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/012339
Other languages
French (fr)
Other versions
WO2000067738A2 (en
Inventor
Juan Eugene De Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Priority to AU49884/00A priority Critical patent/AU774495B2/en
Priority to MXPA01011344A priority patent/MXPA01011344A/en
Priority to EP00932108A priority patent/EP1178791A2/en
Priority to CA2373178A priority patent/CA2373178C/en
Priority to JP2000616765A priority patent/JP4920134B2/en
Publication of WO2000067738A2 publication Critical patent/WO2000067738A2/en
Publication of WO2000067738A3 publication Critical patent/WO2000067738A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)

Abstract

The present invention is directed to a method for the prophylactic and therapeutic treatment of age-related macular degeneration as well as methods for the prophylactic and therapeutic treatment of exudative and atrophic complications of age-related macular degeneration. The methods involve the administration of an inhibitor of the protein tyrosine kinase pathway to an animal, such as a mammal, in particular a human, in an amount sufficient to treat the animal for age-related macular degeneration or an exudative or atrophic complication thereof, respectively, prophylactically or therapeutically. The present invention further provides a method for the prophylactic and therapeutic treatment of degeneration of the retina, a method for the prophylactic and therapeutic treatment of degeneration of the choroid, and a method for the prophylactic and therapeutic treatment of thickening of Bruch's membrane. These methods involve the administration of an inhibitor of the protein tyrosine kinase pathway to an animal, such as a mammal, in particular a human, in an amount sufficient to treat the macula, retina, choroid or Bruch's membrane, respectively, prophylactically or therapeutically. The inhibitor of the protein tyrosine kinase pathway is preferably genistein or an analogue or prodrug thereof or a pharmaceutically acceptable salt of any of the foregoing.
PCT/US2000/012339 1999-05-07 2000-05-05 The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders Ceased WO2000067738A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU49884/00A AU774495B2 (en) 1999-05-07 2000-05-05 The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders
MXPA01011344A MXPA01011344A (en) 1999-05-07 2000-05-05 The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders.
EP00932108A EP1178791A2 (en) 1999-05-07 2000-05-05 The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders
CA2373178A CA2373178C (en) 1999-05-07 2000-05-05 The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders
JP2000616765A JP4920134B2 (en) 1999-05-07 2000-05-05 Use of protein tyrosine kinase pathway inhibitors in the treatment of eye disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13311299P 1999-05-07 1999-05-07
US60/133,112 1999-05-07
US35044099A 1999-07-09 1999-07-09
US09/350,440 1999-07-09

Publications (2)

Publication Number Publication Date
WO2000067738A2 WO2000067738A2 (en) 2000-11-16
WO2000067738A3 true WO2000067738A3 (en) 2001-08-23

Family

ID=26831056

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/012339 Ceased WO2000067738A2 (en) 1999-05-07 2000-05-05 The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders

Country Status (6)

Country Link
EP (1) EP1178791A2 (en)
JP (1) JP4920134B2 (en)
AU (1) AU774495B2 (en)
CA (1) CA2373178C (en)
MX (1) MXPA01011344A (en)
WO (1) WO2000067738A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2826276A1 (en) * 2001-06-20 2002-12-27 Raouf Rekik Ophthalmological medicament for correcting vision and abrogating the need for glasses, contains an angiotension conversion enzyme inhibitor
US7771742B2 (en) * 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
EP1962803A1 (en) * 2005-12-23 2008-09-03 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US10010447B2 (en) 2013-12-18 2018-07-03 Novartis Ag Systems and methods for subretinal delivery of therapeutic agents
EP3744254A4 (en) * 2018-01-25 2021-11-03 Osaka University STRESS STATE DETECTION METHOD AND STRESS DETECTION DEVICE
CN114931574A (en) * 2022-06-14 2022-08-23 深圳爱尔眼科医院 Iron death inhibitor and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040090A1 (en) * 1997-03-14 1998-09-17 The Regents Of The University Of California Methods for inhibiting bacterial cytotoxicity
WO1999045920A2 (en) * 1998-03-13 1999-09-16 Johns Hopkins University School Of Medicine The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09316000A (en) * 1996-05-31 1997-12-09 Toagosei Co Ltd Vaccine for suppressing arterialization
ES2313154T3 (en) * 1996-11-05 2009-03-01 The Children's Medical Center Corporation COMPOSITIONS THAT INCLUDE TALODYMINE AND DEXAMETASONE FOR CANCER TREATMENT.
WO1999016755A1 (en) * 1997-09-26 1999-04-08 Merck & Co., Inc. Novel angiogenesis inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040090A1 (en) * 1997-03-14 1998-09-17 The Regents Of The University Of California Methods for inhibiting bacterial cytotoxicity
WO1999045920A2 (en) * 1998-03-13 1999-09-16 Johns Hopkins University School Of Medicine The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CASAGRANDE F. ET AL: "G1 phase arrest by the phosphatidylinositol 3-kinase inhibitor LY 294002 is correlated to up-regulation of p27(Kip1) and inhibition of G1 CDKs in choroidal melanoma cells.", FEBS LETTERS, (6 FEB 1998) 422/3 (385-390)., XP000971946 *
FAURE VIOLAINE ET AL: "Tyrosine kinase inhibitors and antioxidants modulate NF-kappaB and NOS-II induction in retinal epithelial cells.", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 275, no. 1 PART1, July 1998 (1998-07-01), pages C208 - C215, XP000978431, ISSN: 0002-9513 *
HAYASHI A ET AL: "Genistein, a protein tyrosine kinase inhibitor, ameliorates retinal degeneration after ischemia-reperfusion injury in rat.", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 38, no. 4 PART 1-2, 1997, Annual Meeting of the Association for Research in Vision and Ophthalmology, Parts 1-2;Fort Lauderdale, Florida, USA; May 11-16, 1997, pages S101, XP000978471, ISSN: 0146-0404 *
YOON H.S. ET AL: "Genistein produces reduction in growth and induces apoptosis of rat RPE-J cells.", CURRENT EYE RESEARCH, (2000) 20/3 (215-224)., XP000978532 *

Also Published As

Publication number Publication date
WO2000067738A2 (en) 2000-11-16
CA2373178C (en) 2013-07-02
MXPA01011344A (en) 2004-06-03
AU4988400A (en) 2000-11-21
EP1178791A2 (en) 2002-02-13
AU774495B2 (en) 2004-07-01
JP2002544159A (en) 2002-12-24
CA2373178A1 (en) 2000-11-16
JP4920134B2 (en) 2012-04-18

Similar Documents

Publication Publication Date Title
CA2321560A1 (en) The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
Gros Spasticity—clinical classification and surgical treatment
WO1998010767A3 (en) Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
NO970517D0 (en) Topical ophthalmic formulations containing doxepin derivatives for the treatment of ocular allergy diseases
EP2514420A3 (en) Use of rapamycin for the treatment or prevention of age-related macular degeneration
CA2502437A1 (en) Method and composition containing latanoprost for treating ocular hypertension and glaucoma
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
HK1040185A1 (en) Method for treating and/or preventing retinal diseases with sustained release corticosteroids
CA2213833A1 (en) Vascular endothelial cell growth factor antagonists
TW200833341A (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
MX9702349A (en) Use of 9-deoxy prostaglandin derivatives to treat glaucoma.
CA2265839A1 (en) Noded cuffs for transcutaneous or intrabody prosthetic devices
EP1074258A3 (en) Methods and compositions for treating diseases and conditions of the eye
CA2582316A1 (en) Use of inhibitors of jun n-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
CA2262268C (en) Method of treating impotence due to spinal cord injury
WO2000067738A3 (en) The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders
WO2002047673A3 (en) Methods and compositions to treat conditions associated with neovascularization
WO2002051379A3 (en) Thixotropic nasal spray
WO2002013805A3 (en) Method of treating neurodegenerative disorders of the retina and optic nerve head
EP1037622A4 (en) Taurine derivatives usable in the treatment of ophthalmic disorders
WO2005102303A3 (en) Antiprostaglandins for the treatment of ocular pathologies
AU6418296A (en) Aromatic acid diamides with antigastrin activity, a method for their preparation and their pharmaceutical use
EP1482922A4 (en) Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
WO1998024898A3 (en) Therapeutic composition comprising the kal protein and use of the kal protein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 49884/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2373178

Country of ref document: CA

Ref country code: CA

Ref document number: 2373178

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 2000 616765

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/011344

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2000932108

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000932108

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 49884/00

Country of ref document: AU